Interview: Quintiles India CEO on green shoots, digital patients & white noise
This article was originally published in Scrip
Naz Haji, Quintiles' new country CEO for India, claims there are green shoots in India's beleaguered clinical research segment. Sponsors, he says, are beginning to reassess decisions to move studies away from the country, although he admits the confidence gap may take a while to bridge.
You may also be interested in...
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.